Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |